Based on historical precedence, ABN technology may well have applicability to human vaccines. Technologies that could improve thermal stability, reduce supply chain losses and even provide alternative delivery methods are important considerations in vaccine development and production.

Based on studies by ABN using animal models (see Resources section for published information), it is anticipated that ABN Technology may offer the following opportunities for development of vehicles for human vaccine delivery:

  • Through the use of novel encapsulation and stabilization technology, vaccine formulations could be developed such that some of the traditional “cold-chain” issues may be mitigated.
  • Improving the shelf life of vaccines could extend expiration dates and assist in managing the vaccine supply chain more effectively, thus improving availability.
  • Developing alternative, stable formulations may also be a benefit. For example, developing a stable dry or tableted version of a vaccine that is normally delivered as an oral liquid could improve ease of use and sustainable availability.

While ABN technology may not be applicable to all vaccines, previous ABN research and development efforts using animal models have demonstrated applicability to selected vaccines resulting in efficacy improvements and better shelf stability. The potential for application of ABN vaccine technology is limited to human vaccine delivery, since rights to the technologies for use in non-human animals have been acquired by a third party.